Project Grant R43CA298530
Award Date 9/18/25
Completion Date 8/31/26
Dollars Obligated $400K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $400,000 to Kure Ai Inc. to develop a novel CAR-T cell therapy product targeting the MR1 antigen expressed on the surface of various tumor cells, including acute myeloid leukemia (AML) and glioblastoma. The key objectives are to: 1) assess MR1 expression in primary patient AML and glioblastoma samples, 2) perform mouse efficacy studies using AML and glioblastoma models, and 3)...
- This federal Project Grant award of $400,000 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the advancement of next-generation CAR-T cell therapies for renal cell carcinoma (RCC). The award recipient, Cellinfinity Bio Inc., is developing novel CAR-T cell modifications, including a PRDM1 exon 3 knockout and a CTLA-4 cytoplasmic tail fusion, to enhance CAR-T cell efficacy against RCC tumors. The project aims to evaluate the combination of these...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $399,625.00 to Cellchorus Inc., a Houston-based company specializing in advanced cell analysis technologies, to develop a high-throughput platform for profiling the functional signatures of CAR T cells from patients with relapsed/refractory large B cell lymphoma (r/r LBCL). The goal is to create a scalable, AI-powered imaging technology called Time-lapse Imaging Microscopy in...
- This $195,766 federal Project Grant, awarded on December 19, 2024 by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), supports research at Yale University to develop a mechano-transduction platform for enhancing chimeric antigen receptor (CAR) T-cell therapies for cancer immunotherapy. The key goals are to: 1) measure forces along immune receptors like the T-cell receptor and CAR using force sensors, and 2) engineer force transduction modules that can induce expression of...
- The National Cancer Institute (NCI) awarded Lifengine Animal Health Laboratories Incorporated a $400,000 Project Grant under the Cancer Treatment Research federal grant program (CFDA 93.395). The award period runs from August 4, 2025 to July 31, 2026. The grant funds the development of chimeric antigen receptor (CAR)-T cell therapies that can overcome functional exhaustion by overexpressing the C-MYB transcription factor. This research aims to improve the therapeutic efficacy and duration of...
- This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to Pumpkinseed Technologies Inc. for $353,204 supports the development and demonstration of a novel technology called Cell-MAPP. The goal of this Phase I SBIR project is to create the first system capable of continuously monitoring the state transitions of individual T cells in response to antigen exposure. Cell-MAPP will utilize antigen-multimer barcoding and single-cell TCR sequencing to connect...
- This Project Grant award from the National Science Foundation's Social, Behavioral, and Economic Sciences (CFDA 47.075) program provides $250,000 to Old Dominion University Research Foundation (ODURF) to develop low-cost mRNA-based manufacturing technologies for Chimeric Antigen Receptor (CAR) T-cell therapies. The research aims to address critical issues with current CAR T-cell manufacturing, including safety concerns with viral gene transfer and high costs associated with centralized...
- This Project Grant, awarded by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), funds the development and validation of a novel armored CAR-T immunotherapeutic for the treatment of pancreatic ductal adenocarcinoma (PDAC). The $400,835 award to Cambium Oncology LLC aims to engineer CAR-T cells that can secrete a VIP receptor antagonist to disrupt the immunosuppressive tumor microenvironment in PDAC. The 1-year project involves developing and validating...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $1,031,566 to Mucommune LLC to develop in vivo-engineered B7-H3 chimeric antigen receptor (CAR) T-cells for ovarian cancer therapy. The project aims to leverage a novel viral vector system to directly engineer circulating T-cells in the body, rather than harvesting, modifying, and expanding them ex vivo. This approach has the potential to reduce the time and cost of CAR-T therapy...
- This $1,313,567 federal Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports Cytoagents Inc., a Pittsburgh-based pharmaceutical company, in developing CTO1681 for the prevention and treatment of cytokine release syndrome (CRS) associated with chimeric antigen receptor (CAR) T-cell therapy. CRS is a severe and potentially life-threatening immune-mediated toxicity that can occur with CAR T-cell treatments for hematologic malignancies. The...